T-bet B cells and joint erosion in rheumatoid arthritis
Role of T-bet B cells in rheumatoid arthritis
This work looks at whether a special group of B cells called T-bet B cells drive joint inflammation and bone damage in people with rheumatoid arthritis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11222684 on NIH RePORTER |
What this research studies
As someone with RA, I would learn that researchers are studying a particular B cell type called T-bet B cells that are more common in inflamed joint tissue. They analyze joint tissue and blood from people with RA and run laboratory and mouse experiments to see how these B cells promote bone-eating cells (osteoclasts) and block bone-building cells (osteoblasts). The team compares B cells with and without the T-bet protein to find the signals and receptors that make them harmful in joints. Combining human samples, cell studies, and animal models helps them define how these cells drive ongoing inflammation and joint erosion.
Who could benefit from this research
Good fit: Adults with rheumatoid arthritis, especially those with active synovial inflammation or progressive joint erosion, would be the most relevant people for sample donation or future therapies arising from this work.
Not a fit: People without rheumatoid arthritis, those with other types of arthritis, or patients whose disease is well controlled and not driven by B cell activity may not directly benefit.
Why it matters
Potential benefit: If successful, this work could point to new ways to stop or prevent joint erosion in RA by targeting T-bet B cells or their signals.
How similar studies have performed: Previous studies show B cells can promote bone erosion and that T-bet B cells are linked to worse RA, but directly targeting T-bet B cells is a newer approach with limited prior clinical testing.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Anolik, Jennifer Howitt — University of Rochester
- Study coordinator: Anolik, Jennifer Howitt
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.